• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Intraday Session

    2/10/22 2:51:55 PM ET
    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADGI alert in real time by email

     

    Gainers

    • Dermata Therapeutics (NASDAQ:DRMA) shares moved upwards by 26.1% to $1.35 during Thursday's regular session. The current volume of 17.5 million shares is 7266.3% of Dermata Therapeutics's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $11.2 million.
    • Vaccinex (NASDAQ:VCNX) shares increased by 20.53% to $1.88. As of 12:30 EST, Vaccinex's stock is trading at a volume of 6.1 million, which is 560.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $74.3 million.
    • Oak Street Health (NYSE:OSH) stock moved upwards by 15.02% to $19.25. Trading volume for Oak Street Health's stock is 2.1 million as of 12:30 EST. This is 76.2% of its average full-day volume over the last 100 days. The company's market cap stands at $4.6 billion.
    • I-MAB (NASDAQ:IMAB) shares rose 14.67% to $26.33. Trading volume for this security as of 12:30 EST is 414.0K, which is 65.3% of its average full-day volume over the last 100 days. The company's market cap stands at $2.1 billion.
    • Pulse Biosciences (NASDAQ:PLSE) shares increased by 13.74% to $7.33. Trading volume for Pulse Biosciences's stock is 213.5K as of 12:30 EST. This is 196.0% of its average full-day volume over the last 100 days. The company's market cap stands at $217.0 million.
    • IsoPlexis (NASDAQ:ISO) shares rose 13.47% to $7.41. The market value of their outstanding shares is at $288.6 million.

     

    Losers

    • Adagio Therapeutics (NASDAQ:ADGI) stock decreased by 24.1% to $8.18 during Thursday's regular session. As of 12:30 EST, Adagio Therapeutics's stock is trading at a volume of 7.1 million, which is 84.8% of its average full-day volume over the last 100 days. The company's market cap stands at $910.0 million.
    • ENDRA Life Sciences (NASDAQ:NDRA) shares decreased by 19.65% to $0.45. As of 12:30 EST, ENDRA Life Sciences's stock is trading at a volume of 999.0K, which is 314.3% of its average full-day volume over the last 100 days. The company's market cap stands at $18.9 million.
    • InnovAge Holding (NASDAQ:INNV) stock decreased by 18.05% to $4.5. InnovAge Holding's stock is trading at a volume of 617.4K shares as of 12:30 EST. This is 75.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $609.7 million. The company's, Q2 earnings came out yesterday.
    • Seagen (NASDAQ:SGEN) shares declined by 14.3% to $121.2. As of 12:30 EST, Seagen's stock is trading at a volume of 5.0 million, which is 542.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.1 billion. As per the press release, Q4 earnings came out yesterday.
    • Vera Therapeutics (NASDAQ:VERA) stock declined by 10.46% to $17.06. Trading volume for Vera Therapeutics's stock is 718.4K as of 12:30 EST. This is 1025.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $362.9 million.
    • Integrity Applications (NASDAQ:IGAP) shares decreased by 10.0% to $3.15. The company's market cap stands at $48.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADGI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADGI
    $DRMA
    $IGAP
    $IMAB

    CompanyDatePrice TargetRatingAnalyst
    Vera Therapeutics Inc.
    $VERA
    3/11/2026$88.00Peer Perform → Outperform
    Wolfe Research
    Pulse Biosciences Inc
    $PLSE
    1/30/2026$25.00Outperform
    Mizuho
    Vera Therapeutics Inc.
    $VERA
    10/16/2025$48.00Buy
    BofA Securities
    I-MAB
    $IMAB
    10/3/2025$9.00Outperform
    Leerink Partners
    InnovAge Holding Corp.
    $INNV
    9/18/2025$5.00Underweight
    Analyst
    I-MAB
    $IMAB
    9/9/2025$7.00Buy
    BTIG Research
    Vera Therapeutics Inc.
    $VERA
    8/4/2025Outperform → Peer Perform
    Wolfe Research
    Pulse Biosciences Inc
    $PLSE
    7/7/2025$22.00Outperform
    Oppenheimer
    More analyst ratings

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vera Therapeutics upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Vera Therapeutics from Peer Perform to Outperform and set a new price target of $88.00

    3/11/26 8:30:17 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Pulse Biosciences with a new price target

    Mizuho initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $25.00

    1/30/26 6:44:12 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    BofA Securities initiated coverage on Vera Therapeutics with a new price target

    BofA Securities initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $48.00

    10/16/25 8:29:17 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

    Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment. Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced clinical data on outcomes durability from the nPulse Vybrance Percutaneous Electrode System First-in-Human ablation study of benign thyroid nodules using nsPFA energy. The long-term follow-up from this study demonstrates significant and sustained volume reduction of treated benign thyroid nodules at 15-22 months, with no tissue regrowth and no serious adverse e

    3/9/26 7:00:00 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 46,000 shares of Class A common stock and restricted stock units (RSUs) underlying 25,875 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock

    3/6/26 4:05:00 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Appoints Christopher Hite to Board of Directors

    BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christopher Hite, an accomplished executive with decades of corporate and financial strategy leadership experience in the biopharmaceutical sector, to Vera Therapeutics' Board of Directors. "It is a pleasure to welcome Chris to our Board of Directors at this exciting juncture in Vera Therapeutics' trajectory as we near the potential launch of our first-in-class dual BAFF/APRIL inhibitor for patients with IgA nephropathy," sa

    3/5/26 9:00:22 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    SEC Filings

    View All

    Vera Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Vera Therapeutics, Inc. (0001831828) (Filer)

    3/9/26 5:01:12 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulse Biosciences Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    3/9/26 9:31:47 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Vera Therapeutics Inc.

    SCHEDULE 13D/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    3/5/26 6:11:20 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hite Christopher

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    3/9/26 4:49:21 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Hite Christopher

    3 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    3/9/26 4:47:13 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Tokman Alexander Y was granted 26,921 shares, increasing direct ownership by 36% to 101,926 units (SEC Form 4)

    4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

    3/4/26 9:48:18 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Enright Patrick G bought $249,985 worth of shares (5,882 units at $42.50) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    12/15/25 8:07:34 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Duggan Robert W bought $2,788,624 worth of shares (192,599 units at $14.48), increasing direct ownership by 0.41% to 47,709,140 units (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    9/12/25 8:14:18 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Director Enright Patrick G bought $5,277,311 worth of shares (250,000 units at $21.11) (SEC Form 4)

    4 - Vera Therapeutics, Inc. (0001831828) (Issuer)

    6/25/25 8:07:16 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Leadership Updates

    Live Leadership Updates

    View All

    Vera Therapeutics Appoints Christopher Hite to Board of Directors

    BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christopher Hite, an accomplished executive with decades of corporate and financial strategy leadership experience in the biopharmaceutical sector, to Vera Therapeutics' Board of Directors. "It is a pleasure to welcome Chris to our Board of Directors at this exciting juncture in Vera Therapeutics' trajectory as we near the potential launch of our first-in-class dual BAFF/APRIL inhibitor for patients with IgA nephropathy," sa

    3/5/26 9:00:22 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

    BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Matt Skelton to Chief Commercial Officer, effective immediately. Mr. Skelton joined Vera Therapeutics over a year ago as the Executive Vice President, Commercial. "We are pleased to welcome Matt to the executive team as we prepare for the potential commercial launch of atacicept for the treatment of IgA nephropathy," said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. "With his track record

    1/28/26 7:30:00 AM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Financials

    Live finance-specific insights

    View All

    Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025. Recent Business Highlights Endocardial Catheter AF Ablation Highlighted 100% procedural success, or freedom from atrial fibrillation (AF), at 6 months and 96% procedural success at one year, of evaluable patients, following treatments with the nPulse Cardiac Catheter System in the first-in-human feasibility study which was presented as late-breaking data at the 31st Annual AF Symposium Meeting. Receiv

    2/19/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 7647402. A live and recorded webcast of the event will be available on the Pulse Bioscie

    2/4/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    InnovAge Announces Financial Results for the Fiscal Second Quarter Ended December 31, 2025

    DENVER, Feb. 03, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. ("InnovAge" or the "Company") (NASDAQ:INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), today announced financial results for its fiscal second quarter ended December 31, 2025. "InnovAge delivered strong operating and financial results this quarter, reflecting continued progress in building a scalable, high-quality PACE platform," said Patrick Blair, CEO. "Our performance is rooted in disciplined execution and a care model that prioritizes clinical outcomes, participant experience, and respon

    2/3/26 4:05:00 PM ET
    $INNV
    Medical/Nursing Services
    Health Care

    $ADGI
    $DRMA
    $IGAP
    $IMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

    SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

    11/18/24 4:15:28 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vera Therapeutics Inc.

    SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)

    11/14/24 4:10:28 PM ET
    $VERA
    Biotechnology: Pharmaceutical Preparations
    Health Care